Arrowhead Research (ARWR) +5.3% premarket after a study of its RNAi-based candidate ARC-520 in a...

|About: Arrowhead Pharmaceuticals (ARWR)|By:, SA News Editor

Arrowhead Research (ARWR) +5.3% premarket after a study of its RNAi-based candidate ARC-520 in a chimpanzee chronically infected with the human hepatitis B virus supports findings from rodent models indicating it can knock down hepatitis B virus DNA and key viral antigens.